Replies to post #121666 on Biotech Values

[oc631]

More trials have to be done to determine if the Koronis drug can essentially take down the HIV virus, but at least one analyst believes it could be a game changer. Katherine Xu, a biotech analyst for William Blair, said in a report earlier this year that the Koronis drug has “huge potential for disruption.” One scenario she paints: that the Koronis drug be given in combination with an existing drug like Atripla and “after a year or so, the viruses could be mutated out of existence and the patients could achieve a cure,” Xu wrote in a report for Wedbush Securities, where she worked until recently. “If it were to be successful, it would be great news for the field,” Xu told me last week in a phone interview.

This appears to be one way to create a viral strain resistant to Atripla. I wonder how quickly this trial will enroll?

[BTH]

Interesting.

Well beyond my area of expertise, so I ask: is creating a mutation of HIV effectively creating the possibility of another strain of a super
virus?

[biomaven0]

Here's a better article on Koronis:

http://www.thebody.com/content/art58413.html